Who are Pletaal SR capsule's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cilostazol Tablets, Probucol and Cilostazol, Cilostazol group, Milrinone Lactate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pletaal-sr-capsule.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pletaal SR capsule — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pletaal SR capsule (Pletaal SR capsule) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase-3 inhibitor. Area: Cardiovascular.

marketed Phosphodiesterase-3 inhibitor PDE-3 (phosphodiesterase-3) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Pletaal SR capsule (Pletaal SR capsule) — Korea Otsuka Pharmaceutical Co., Ltd.. Cilostazol inhibits phosphodiesterase-3 (PDE-3) to increase cAMP levels, promoting vasodilation and inhibiting platelet aggregation.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pletaal SR capsule TARGET	Pletaal SR capsule	Korea Otsuka Pharmaceutical Co., Ltd.	marketed	Phosphodiesterase-3 inhibitor	PDE-3 (phosphodiesterase-3)
Cilostazol Tablets	Cilostazol Tablets	Gyeongsang National University Hospital	marketed	Phosphodiesterase-3 inhibitor	PDE-3 (Phosphodiesterase-3)
Probucol and Cilostazol	Probucol and Cilostazol	Otsuka Beijing Research Institute	marketed	Antioxidant/lipid-lowering agent combined with phosphodiesterase-3 inhibitor	Probucol: lipid peroxidation inhibitor; Cilostazol: phosphodiesterase-3 (PDE-3)
Cilostazol group	Cilostazol group	Otsuka Beijing Research Institute	marketed	Phosphodiesterase-3 inhibitor	PDE-3 (Phosphodiesterase-3)
Milrinone Lactate	Milrinone Lactate	Pfizer Inc.	marketed	Inotropic agent; Phosphodiesterase-3 inhibitor; Vasodilator	Phosphodiesterase-3 (PDE-3) enzyme

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase-3 inhibitor class)

Gyeongsang National University Hospital · 1 drug in this class
Korea Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class
Otsuka Beijing Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pletaal SR capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/pletaal-sr-capsule. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing